Jong Yu currently serves as a Scientific Director at GSK, focusing on immuno-oncology and combinations research, with significant contributions to clinical trials targeting the CD226 axis and novel target discovery through CRISPR-based cell line screens. As a member of the leadership team since 2021, Jong oversees pipeline strategy, daily operations, and talent management, leading a team of nine scientists. Prior experience includes a post-doctoral position at Princeton University, where Jong conducted biochemical and structural analysis of apoptosis and NF-kB signaling, and earlier roles at GSK as an Investigator in molecular medicine and immuno-oncology, as well as immuno-inflammation. Jong holds a Ph.D. in Pharmacology/Biochemistry from the University of Pennsylvania School of Medicine.
This person is not in any teams
This person is not in any offices